Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10703592 | 0.79 | SMN1; SMN2 (0.50) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL1068372 | 0.79 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL11821044 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3075421 | 0.70 | ADORA2A (0.75) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL6371765 | 0.68 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3047080 | 0.68 | ADORA2A (0.47) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL637552 | 0.67 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL25620 | 0.67 | PDE4A (1.00) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3951708 | 0.67 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL2010225 | 0.67 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-102633730-A | Substituted piperazines as cb1 antagonists | SCHERING CORP | 2012-08-15 | — | — | CN | disclosed |
| CN-102558075-A | Substituted piperazines as CB1 antagonists | SCHERING CORP | 2012-07-11 | — | — | CN | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| CN-101297969-B | Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications | SCHERING CORP | 2011-03-09 | — | — | CN | disclosed |
| CN-1915429-B | Combinations of the peroxisome proliferator-activated receptor (ppar) activator and sterol absorption inhibitor | SCHERING CORP | 2010-12-15 | — | — | CN | disclosed |
| CN-101785772-A | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | SCHERING CORP | 2010-07-28 | — | — | CN | disclosed |
| CN-100571701-C | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2009-12-23 | — | — | CN | disclosed |
| CN-1756756-A | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | SCHERING CORP (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1756755-A | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | SCHERING CORP (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | disclosed |
| CN-1659161-A | Piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1646165-A | Combinations of peroxisome proliferator-activated receptor (PPAR) activators and sterol absorption inhibitors and treatment of vascular indications | SCHERING CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| CN-1556700-A | Methods of treating or preventing vasculitis using sterol absorption inhibitors | ���鹫˾ | 2004-12-22 | — | — | CN | disclosed |
| CN-1527707-A | The use of substituted azetidinone compounds for the treatment of sitosterolemia | ���鹫˾ | 2004-09-08 | — | — | CN | disclosed |
| CN-1137100-C | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | ��ʲ | 2004-02-04 | — | — | CN | disclosed |
| CN-1139430-A | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | PI4KA 263/4885PI4K2B 310/4885PI4K2A 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.